Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAurinia Pharmaceuticals Inc
-
Registration countryCanada
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









